Micromedic Technologies (TASE: MCTC) announced successful results of a clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology.Read More
Theralase Technologies (OTCQX:TLTFF; TSXV:TLT) recently identified a new platform of super potent anti-cancer drugs, or PDCs, discovered by Dr. Sherri McFarland, Professor, Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, the original inventor of the Theralase licensed ruthenium-based PDCs.Read More
William Blair launched coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating. The stock closed at $16.05 on Oct. 5.Read More
Roth Capital Markets launched coverage on Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and $2 price target. The stock closed at 77 cents on April 19.Read More
H.C. Wainwright initiated coverage of Calithera Biosciences (NASDAQ:CALA) with a “buy” rating and $9 price target. The stock closed at $3.95 on Jan. 5.Read More
Ladenburg Thalmann launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $2.70 price target. The stock closed at $1.24 on Dec. 20.Read More
A new study of Antibe Therapeutics’ (OTCQB:ATBPF; TSX-V:ATE) ATB-346 drug candidate has shown promising results in the chemoprevention and treatment of melanoma in mice.
The article was published online in the September issue of the peer-reviewed journal, Pharmacological Research. It can be viewed here.Read More
Roth Capital Partners raised its price target for Bionomics (ASE:BNO; OTCQX:BNOEF) to (Australian) $2.50 from $1.50 after the company’s Phase 2 BNC210 trial met its primary and secondary endpoints in treating generalized anxiety disorder (GAD) in an acute setting. The stock closed at 27 cents on Tuesday.
Analyst Joseph Pantginis writes that there are two key takeaways from the study: brain systems involved with anxiety are being engaged effectively and the data significantly increase the partnering potential for BNC210. Merck (NYSE:MRK) has already signed two separate partnerships with Bionomics.Read More